Financial Statements

NGM Biopharmaceuticals, Inc. (NGM)


-0.06 (-0.36%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -299-196-147-147-
Net Income --102-43-0-14
Stock Dividends 299--6--133
Dividend Paid -----
Retained Earnings --299-196-147-147

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 15192425-
Annual Depreciation -13-3-1531
Capital Expenditure -2-2-3-6-6
Net PPE -15192425

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -217-134-134-178-
Intangible and Goodwill -----

NGM Biopharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes NGM Biopharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.